JP Morgan Chase’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
JP Morgan Chase's BDTX Position: Q3 2026 in Review
JP Morgan Chase increased its Black Diamond Therapeutics (BDTX) stake by 8.3% in Q3 2026, buying an estimated $4.78K and bringing the position to 31,683 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6495.
JP Morgan Chase first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $11.5M in Q4 2020. 111 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- JP Morgan Chase held 31,683 shares of Black Diamond Therapeutics worth $59.2K as of Q3 2026.
- JP Morgan Chase bought 2,441 Black Diamond Therapeutics shares in Q3 2026, an estimated $4.78K.
- Black Diamond Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #6495 holding.
- JP Morgan Chase first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
- JP Morgan Chase's Black Diamond Therapeutics position peaked at $11.5M in Q4 2020.
- 111 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.